The momentum created from our entry into the clinic has also extended to the research pipeline. Here we are focusing on our Sofra platform due to the ongoing external interest and some favourable tailwinds, and the team has been busy expanding our SOF-VAC portfolio to make it even more attractive to the market. We have also begun identifying how our Sofra platform could be used in the cancer space, as there is an important link between inflammation and the disease that is well worth investigating further. Looking at the wider picture, the Sofra platform is so promising because it can be used to tackle inflammation that is present in many diseases from rheumatoid arthritis and diabetes to skin conditions like psoriasis and many others. Our challenge is to select and develop the best assets from our pipeline so they will in due course attract commercial attention. We will continue to keep the market updated on our progress and, on behalf of the Board, I would like to thank all of our shareholders for your support. It is very much appreciated as we continue to transform Noxopharm and build a successful company. Yours sincerely, Fred Bart Chairman Annual Report 2025 6
RkJQdWJsaXNoZXIy MjE2NDg3